Community oncology plays a central role in the US health care system, offering high-quality care that is both accessible and ...

The FDA has granted priority review to the supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) ...

t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies ...

As previously presented at the 2025 European Society for Medical Oncology (ESMO) Annual Congress, the combination ...

In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...

Dr. Shune highlights that the growing availability of FDA-approved agents with distinct and complementary mechanisms has ...

Dr. Shune concludes the discussion by focusing on safety, sequencing, and practical considerations for incorporating ...

Overall, this segment establishes a nuanced view of prognosis that avoids binary categorization. Instead, Dr Shaheen frames ...

For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).

The FDA has updated the safety labeling for the chemotherapeutic agents capecitabine (Xeloda) and fluorouracil (5-FU) to ...

Bruton tyrosine kinase inhibitors (BTKis) are a cornerstone of chronic lymphocytic leukemia (CLL) therapy, with newer second-generation agents developed to maintain efficacy while improving ...

Azacitidine plus venetoclax boosts response rates in therapy-related high-risk MDS, enabling transplant bridging despite frequent severe cytopenias and infection risk.